In contrast to a recent study of 17,187 HCV patients with a combined 104,000 interval years of follow-up, which reported that achieving SVR with DAAs reduced HCC risk more than IFN (aHR: 0.29, 95% CI: 0.17–0.48), our study confirmed that the treatment regimen itself may not be an independent risk factor for HCC (aHR: 1.43, 95% CI: 0.88–2.35) after adjusting for pretherapy age, sex, viral factors, fibrosis status, and other variables. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.